MENU
+Compare
KNBIF
Stock ticker: OTC
AS OF
Jan 17 closing price
Price
$0.07
Change
-$0.01 (-12.50%)
Capitalization
9.55M

KNBIF Kane Biotech Inc. Forecast, Technical & Fundamental Analysis

Industry Biotechnology
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for KNBIF with price predictions
Jan 08, 2025

KNBIF's Stochastic Oscillator stays in overbought zone for 4 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for KNBIF entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KNBIF's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on KNBIF as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KNBIF just turned positive on December 31, 2024. Looking at past instances where KNBIF's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where KNBIF advanced for three days, in of 46 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.744). P/E Ratio (1.870) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). KNBIF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.887) is also within normal values, averaging (264.079).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KNBIF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KNBIF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
290-100 Innovation Drive
Phone
+1 204 453-1301
Employees
N/A
Web
https://www.kanebiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITEIX10.840.07
+0.65%
VY® T. Rowe Price Equity Income I
RNWGX77.800.35
+0.45%
American Funds New World R6
NDVCX16.940.07
+0.41%
MFS New Discovery Value C
BMSLX14.640.06
+0.41%
MFS Blended Research Mid Cap Eq I
PAXDX8.940.03
+0.34%
Impax Global Sustainable Infras Inv

KNBIF and Stocks

Correlation & Price change

A.I.dvisor tells us that KNBIF and CADL have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNBIF and CADL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNBIF
1D Price
Change %
KNBIF100%
-3.07%
CADL - KNBIF
22%
Poorly correlated
-13.33%
LQDA - KNBIF
21%
Poorly correlated
+3.04%
SPHDF - KNBIF
20%
Poorly correlated
N/A
MMIRF - KNBIF
12%
Poorly correlated
N/A
IGXT - KNBIF
7%
Poorly correlated
N/A
More